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Purpose: microRNAs (miRNAs) mediate the pathological mechanisms of diabetic
retinopathy. In this study, we compared miRNA expression profiles in the vitreous
between patients with proliferative diabetic retinopathy (PDR) and patients with a
macular hole as non-diabetic controls, and between PDR patients treated with anti-
vascular endothelial growth factor (VEGF) therapy and untreated PDR patients.
Methods:Vitreous samples of non-diabetic and PDRpatientswere screened formiRNAs
with quantitative polymerase chain reaction (qPCR) panels. miRNA candidates were
validated in vitreous samples of a second, independent cohort. In addition, the effect of
anti-VEGF therapy was investigated in the vitreous of a third study population consist-
ing of PDR patients who had not received anti-VEGF therapy and PDR patients who had
received preoperative anti-VEGF therapy.
Results: During screening, seven miRNAs were found to be significantly higher in the
vitreous of PDR patients, whereas two miRNAs were found to be significantly lower
compared with non-diabetic controls. Validating the expression of these miRNAs in
a second cohort resulted in the identification of six miRNAs that were expressed at
significantly higher rates in the vitreous of PDR patients: hsa-miR-20a-5p, hsa-miR-23b-
3p, hsa-miR-142-3p, hsa-miR-185-5p, hsa-miR-326, and hsa-miR-362-5p. Among these
six miRNAs, hsa-miR-23b-3p levels were lower in the anti-VEGF-treated group of PDR
patients compared with untreated PDR patients.
Conclusions: In this study, we identified six miRNAs that are expressed more highly in
PDR patients and onemiRNA that is expressed at a lower levels in anti-VEGF-treated PDR
patients.
Translational Relevance: miRNAs identified in the vitreous of PDR patients may
improve our understanding of the mechanisms leading to PDR.
Copyright 2020 The Authors
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Introduction
Diabetic retinopathy (DR) is a vision-threatening
complication of diabetes and an important cause of
blindness worldwide.1 It is a multistage disease that
develops slowly and can be divided clinically into a
non-proliferative or a proliferative state. The latter is
referred to as proliferative diabetic retinopathy (PDR),
which is characterized by retinal neovascularization
and ultimately vision loss.2,3 Even though photoco-
agulation or anti-vascular endothelial growth factor
(VEGF) therapy offers treatment options, treatment
success is quite variable.4,5 Furthermore, the mecha-
nisms driving DR are still not completely understood,
so a deeper understanding of them has the potential to
lead to new and improved therapies.6
The expression of microRNAs (miRNAs) is altered
in DR and is anticipated to contribute to disease
progression.7–9 miRNAs are small, non-coding RNAs,
19 to 22 nucleotides in length, that regulate gene expres-
sion by inhibiting messenger RNA translation.10,11 In
addition, they are highly stable in body fluids,12 as
they either are actively secreted from cells or passively
accumulate due to cellular processes such as apopto-
sis.13–15 Once in a body fluid, miRNAs can be taken
up by cells and consecutively modulate their gene
expression.14 The expression of vitreal miRNAs is also
changed in various vitreoretinal diseases,16–22 suggest-
ing that vitreal miRNAsmay influence disease progres-
sion.
Which miRNAs are differently expressed in the
human vitreous during PDR is still largely unexplored.
Furthermore, correctly measuring and interpreting
miRNA expression in the vitreous is challenging due
to the lack of valid internal controls.23
In this study, we therefore aimed to identify
miRNAs that are differently expressed in the vitreous
of PDR patients compared with non-diabetic control
patients. Furthermore, we investigated whether or not
preoperative anti-VEGF therapy in PDR was associ-
ated with an altered miRNA expression profile.
Materials and Methods
Study Population
Vitreous samples were obtained from the University
of Newcastle upon Tyne. A favorable ethical opinion
for the collection of the samples was obtained from
the National Health Service (NHS) research ethics
committee (South East Coast-Surrey Research Ethics
Committee reference 12/LO/0130), and the collection
was carried out at Sunderland Eye Infirmary under
the sponsorship of the City Hospitals Sunderland
NHS foundation trust. After the aims of the study
were explained, written consent was obtained from
all patients, and the study was conducted according
to the Declaration of Helsinki. Consecutive patients
undergoing vitrectomy for the complications of either
a macular hole or PDR were recruited by one surgeon
from 2015 to 2018. Eyes with previous vitrectomy
surgery were excluded. Eyes with active PDR were
pretreated with bevacizumab, ranibizumab, or afliber-
cept 2 to 5 days prior to vitrectomy. All clinical
variables were determined by a single experienced
retinal specialist.
Patient characteristics can be found in Table 1.
A screening cohort was used initially for a screen-
ing purposes; it consisted of 10 vitreous samples from
patients with macular holes as controls and 10 samples
from PDR patients. There was no statistically signif-
icant difference in age or gender ratio between the
control and PDR patients.
A second cohort, the confirmation cohort, consisted
of 28 patients, including 17 control and 11 PDR
patients, and was used for confirmation of the identi-
fied miRNAs. There was no statistically significant
difference in age or gender ratio between control and
PDR patients. The HbA1c value for one patient could
not be retrieved.
Finally, a third cohort of patients, the anti-VEGF
cohort, was used to compare untreated and anti-
VEGF-treated patients. Of 33 PDR patients, 17 had
received preoperative anti-VEGF treatment (PDR(+))
in the form of bevacizumab (n = 10), ranibizumab (n
= 1), or aflibercept (n = 6), and 16 of them had not
received any anti-VEGF therapy and were referred to
as PDR(–). The samples of 8 of the 16 patients without
anti-VEGF treatment were also used in the confir-
mation cohort. There were no statistically significant
differences in age, gender ratio, duration of diabetes, or
HbA1c concentration between patients with or without
anti-VEGF therapy. The HbA1c value of one patient
in each group is not known. In addition, no statis-
tically significant differences were found between the
two different pretreatment groups (bevacizumab +
ranibizumab vs. aflibercept) (Table 1).
RNA Isolation
RNA was isolated using either the miRCury RNA
Isolation Kit (#300112; Exiqon, Vedbaek, Denmark)
for the vitreous samples of the screening study group or
the miRNeasy Serum/Plasma Advanced Kit (#217204;
Qiagen, Hilden, Germany) for the vitreous samples
of the remaining two study groups. The difference
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Table 1. Patient Characteristics
Gender Diabetes Mellitus
Age (y), Duration (y), HbA1c (mmol/mol),
Cohort mean ± SD Female, n (%) Male, n (%) mean ± SD mean ± SD
Screening cohort
Controls (n = 10) 66.0 ± 5.2 5 (50) 5 (50) — —
PDR (n = 10) 64.7 ± 6.1 5 (50) 5 (50) 26.7 ± 14.6 96.3 ± 22.6
P 0.614 1.000
Confirmation cohort
Controls (n = 17) 71.1 ± 3.9 12 (71) 5 (29) — —
PDR (n = 11) 69.1 ± 9.0 4 (36) 7 (64) 20.1 ± 7.2 74.9 ± 10.9
P 0.417 0.079
Anti-VEGF cohort
Untreated PDR (n = 16) 59.1 ± 13.4 8 (50) 8 (50) 21.7 ± 10.0 78.2 ± 20.8
Treated PDR (n = 17) 50.6 ± 13.3 6 (35) 11 (65) 22.5 ± 9.2 79.0 ± 22.0
P 0.076 0.409 0.817 0.918
Bevacizumab +
ranibizumab (n = 11)a
47.1 ± 10.6 4 (36) 7 (64) 19.5 ± 7.4 84.7 ± 20.0
Aflibercept (n = 6) 57.0 ± 16.3 2 (33) 4 (67) 27.8 ± 10.6 69.5 ± 23.7
P 0.149 0.908 0.076 0.190
P < 0.05 was considered to be statistically significant.
aThis group includes 10 patients pretreated with bevacizumab and one patient pretreated with ranibizumab.
in isolation kits is a consequence of the integration
of Exiqon into Qiagen in October 2017, when the
miRCury Kit of Exiqon became no longer available.
Vitreous samples were thawed on ice and centrifuged
(14,000×g, 15 minutes, 4°C); 200 μl of clear super-
natant was then transferred to a fresh tube, and RNA
was isolated according to the respective manufacturer’s
instructions. The isolation step was performed with
various spike-ins, including UniSP2 (2 fmol), UniSP4
(0.02 fmol), UniSP5 (0.0002 fmol), UniSP6 (0.15
fmol), and cel-miR-39-3p (0.002 fmol), all of which
are synthetic RNAs (#203203; Exiqon) that served
as exogenous controls, as well as 10 ng of glycogen
(Invitrogen, Carlsbad, CA, USA). RNA was eluted
with 50 μl of RNase free water and stored as aliquots
of 8 μl at –80°C until further use.
miRNA qPCR
To identify miRNAs of interest, miRNA expression
wasmeasured in the screening cohort using theHuman
microRNAPCRPanel I (V4.M, #203617; Exiqon).We
chose quantitative polymerase chain reaction (qPCR)
panels, because they offer a focused search and are
more sensitive than hybridization panels,24,25 thus
increasing the chance of detecting miRNAs expressed
at potentially low abundance in the vitreous.
In subsequent experiments, the expression of
hsa-miR-20a-5p, hsa-miR-23b-3p, hsa-miR-142-
3p, hsa-miR-185-5p, and hsa-miR-199a-5p was
measured using the Qiagen miRCURY SYBR
Green system. Because hsa-miR-223-3p, hsa-miR-
326, hsa-miR-362-5p, and hsa-miR-662 could not
be detected with this system, their expression was
measured using TaqMan Advanced miRNA Assays
(#A28007 and #4444557; Thermo Fisher Scientific,
Waltham, MA, USA). All reactions were run in dupli-
cate.
In the confirmation cohort, the expression of hsa-
miR-20a-5p, hsa-miR-23b-3p, hsa-miR-142-3p, hsa-
miR-185-5p, and hsa-miR-199a-5p was measured with
the Qiagen system for 17 control and 11 PDR samples,
and the expression of hsa-miR-223-3p, hsa-miR-326,
hsa-miR-362-5p, and hsa-miR-662 was measured with
the TaqMan assays for 17 control and 8 PDR samples.
In the anti-VEGF cohort, the expression of hsa-miR-
20a-5p, hsa-miR-23b-3p, hsa-miR-142-3p, and hsa-
miR-185-5p was measured with the Qiagen system for
16 PDR(–) and 17 PDR(+) samples, and the expression
of hsa-miR-326 and hsa-miR-362-5p was measured
with the TaqMan assays for 13 PDR(–) and 16 PDR(+)
samples. The difference in samples sizes within the
two cohorts can be explained by vitreous being used
up while measuring hsa-miR-223-3p, hsa-miR-326,
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hsa-miR-362-5p, and hsa-miR-662 with the Qiagen
miRCURY system. To check for blood or hemolysis
as a source of miRNA expression in our samples, we
additionally measured the expression of hsa-miR-451
and hsa-miR-144, two miRNAs indicative of hemoly-
sis.26
All experiments were performed following the
respective manufacturer’s instructions and run on an
ABI ViiA7 real-time PCR system (Applied Biosys-
tems, Foster City, CA,USA). AsRNA concentration is
frequently below 2 ng/μl in body fluids and thus cannot
be reliably measured with a spectrophotometer,27 using
a constant input volume of RNA is recommended. The
array was run with 16 μl input RNA, and the SYBR
Green and TaqMan assays were run with 4 μl and 2 μl
input RNA, respectively. A detailed overview of exper-
iment parameters, kits, and primers used can be found
in Supplementary Table S1.
PCR Data Analysis
Raw qPCR data were analyzed using QuantStu-
dio Real-Time PCR System software (Applied Biosys-
tems). Ct values were converted to arbitrary absolute
amounts (2−Ct × 1E12) and expressed as fold change
compared with controls.
In the screening cohort, miRNAs expressed in fewer
than 70% of samples in both the control group and the
PDR group were not considered representative for a
difference in controls and PDR and were omitted from
further analysis (Supplementary Table S2).
Normalization
In the screening cohort, different normalization
methods (i.e., global mean,28 UniSp3 IPC, UniSp2,
UniSp4, UniSp5, UniSp6, cel-miR-39-3p, and snoU6)
were compared. snoU6 was expressed in only 8 out
of 20 samples and could therefore not be used for
normalization. Ct values of all selected miRNAs under
investigation were converted to arbitrary absolute
amounts (2–Ct × 1E12). The coefficient of variation
(CV), equal to (SD/mean) × 100%, of each miRNA
under each method of normalization was then calcu-
lated separately for the controls-only sample set
(Supplementary Fig. S1A) and the complete sample
set (Supplementary Fig. S1B). No normalization,
global normalization, and normalization by UniSp3
IPC gave the lowest CV, and there were no significant
differences between no normalization and global
normalization; all other normalization methods
resulted in significantly higher CVs compared with
that of no normalization. Because global normaliza-
tion or normalization by UniSP3 IPC could not be
applied in the confirmation and anti-VEGF cohorts,
we opted to use no normalization in all cohorts.
miRNA Target Analysis
Validated targets were extracted from miRTarBase
7.0.29 Predicted targets were extracted from miRWalk
3.0.30 To limit the number of validated and predicted
targets, we focused on genes with elevated protein levels
in the vitreous of PDR patients according to Klaassen
et al.31
Statistical Analysis
Statistical analysis was performed using GraphPad
Prism 8.0.1 for Mac (GraphPad Software, La Jolla,
CA, USA; www.graphpad.com). For the screening
analysis, a two-tailed Mann–Whitney U test was used
to detect a statistically significant difference between
the groups. For further qPCR experiments, a one-tailed
Mann–Whitney test was used to confirm a statisti-
cally significant difference if not indicated otherwise.
P < 0.05 was considered statistically significant.
Results
Identification of miRNAs Differently
Expressed in the Vitreous of PDR Patients
and Controls
To identify miRNAs differently expressed in the
vitreous of PDR patients compared with patients with
a macular hole (MH) as non-diabetic controls, we
measured the expression of multiple miRNAs with a
qPCR panel. In the vitreous of control patients, 24
miRNAs were regularly expressed, being defined as
miRNAs that are detectable in at least 70% of the
samples of one group. In the vitreous samples of PDR
patients, 26 miRNAs were regularly expressed (Supple-
mentary Table S2).
Of these miRNAs, hsa-miR-20a-5p, hsa-miR-23b-
3p, hsa-miR-142-3p, hsa-miR-185-5p, hsa-miR-223-
3p, hsa-miR-362-5p, and hsa-miR-662 expression
levels were significantly higher in the vitreous of
PDR patients as compared to controls, whereas hsa-
miR-199a-5p and hsa-miR-326 levels were significantly
lower (Fig. 1). Two miRNAs related to hemolysis,
hsa-miR-451 and hsa-miR-144, did not show elevated
levels in the vitreous of PDR patients as compared to
controls.
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Figure 1. Expression levels of miRNAs in the vitreous that were
significantly different between control andPDRpatients. The expres-
sion levels of miRNAs in the screening cohort consisted of control
and PDR samples (control, n= 10; PDR, n= 10). The expression levels
are shown as the means of absolute amounts with standard devia-
tions as compared with controls on a log10 scale. The expression
levels of hsa-miR-20a-5p, hsa-miR-23b-3p, hsa-miR-142-3p, hsa-miR-
185-5p, hsa-miR-199a-5p, hsa-miR-223-3p, hsa-miR-326, and hsa-
miR-362-5p are relative to the control group. The expression levels
of hsa-miR-662 were calculated as absolute amounts (2−Ct × 1E12).
*P < 0.05, **P < 0.01, and ***P < 0.001.
Confirmation of Different miRNA Expression
in a Cohort of PDR Patients and Controls
To verify our screening results, we measured the
expression of these eight miRNAs in a second,
independent cohort of PDR patients and non-diabetic
MH controls. The expression of hsa-miR-20a-5p, hsa-
miR-23b-3p, hsa-miR-142-3p, hsa-miR-185-5p, and
hsa-miR-199a-5p was measured with Qiagen reagents,
and the expression of hsa-miR-223-3p, hsa-miR-
326, hsa-miR-362-5p, and hsa-miR-662 was measured
with TaqMan reagents. The levels of hsa-miR-20a-
5p, hsa-miR-23b-3p, hsa-miR-142-3p, hsa-miR-185-
5p, hsa-miR-326, and hsa-miR-362-5p were signifi-
cantly higher in the vitreous of PDRpatients compared
with controls, whereas the expression levels of hsa-
miR-199a-5p and hsa-miR-223-3p were not signifi-
cantly different (Fig. 2). The expression of miR-662
could not be detected.
Anti-VEGF Treatment is Associated with a
Lower Expression of hsa-miR-23b-3p in the
Vitreous of PDR Patients
To investigate the effect of anti-VEGF treatment
on the miRNAs that had significantly higher levels in
PDR patients (hsa-miR-20a-5p, hsa-miR-23b-3p, hsa-
miR-142-3p, hsa-miR-185-5p, hsa-miR-326, and hsa-
miR-362-5p), wemeasured their expression in the vitre-
ous of a third study group consisting of patients with
PDR who had or had not received anti-VEGF treat-
ment prior to surgery.
The level of hsa-miR-23b-3p was significantly lower
(3.5-fold, P = 0.02) in the vitreous of patients with
anti-VEGF therapy compared with PDR patients
without anti-VEGF treatment; the expression levels
of the other miRNAs were not significantly differ-
ent (Figs. 3A, 3B). There were no significant differ-
ences in miRNA expression between patients with type
1 diabetes and those with type 2 diabetes (data not
shown).
miRNAs of Interest Are Related to Proteins
That Are Increased in Vitreous of PDR
Patients
To estimate possible functions of hsa-miR-20a-
5p, hsa-miR-23b-3p, hsa-miR-142-3p, hsa-miR-185-
5p, hsa-miR-326, and hsa-miR-362-5p, we analyzed
validated and predicted targets of these miRNAs.
Within these targets, we focused on proteins that are
differently expressed in the vitreous of PDR patients31
and are associated with DR.
All six miRNAs are predicted to target proteins
that are elevated in DR,31 such as bone morphogenetic
protein 2 or angiopoietin 1 (Table 2), or are associated
with angiogenesis and wound healing responses, major
processes involved in PDR (VEGF, angiopoietin-2, or
connective tissue growth factor [CTGF]). VEGF-A is a
confirmed target protein for hsa-miR-20a-5p and hsa-
miR-185-5p.
Discussion
In the present study, our aims were to identify
differently expressed miRNAs in the vitreous of PDR
patients compared to the vitreous of non-diabetic
MH patients and to determine whether the expres-
sion of these miRNAs was different after preoperative
anti-VEGF treatment. We chose patients with MH as
controls, because sufficient numbers of patients under-
going vitrectomy are available, this condition has the
least retinovascular pathology compared to other eye
conditions, and the patients are non-diabetic.
The Change of Vitreal miRNA Expression in
PDR Patients
We found 24 miRNAs regularly expressed in the
vitreous of control patients and 26 miRNAs regularly
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Figure 2. Expression levels of miRNAs in the vitreous of the confirmation cohort. The expression levels of miRNAs with a significant differ-
ence in the screening cohort were measured in control and PDR samples of a second, larger cohort. The expression levels are shown as
absolute amounts on a log10 scale relative to the control group. Box plots indicate median, minimum, and maximum and first and third
quartiles. Symbols on the x-axis represent individuals without detectable expression. *P < 0.05, **P < 0.01, and ***P < 0.001.
Figure 3. Expression levels of miRNAs in the vitreous with andwithout anti-VEGF therapy. The expression levels of miRNAsweremeasured
in the vitreous of patients with PDR who had not received anti-VEGF treatment, PDR(–) and in the vitreous of patients who had received
anti-VEGF treatment, PDR(+). For hsa-miR-23b-3p, the expression levels are shown as absolute amounts on a log10 scale relative to the
PDR(–) group. Box plots indicate median, minimum, andmaximum and first and third quartiles. (A) The symbol on the x-axis represents one
individual without detectable expression. (B) For hsa-miR-20a-5p, hsa-miR-142-3p, hsa-miR-185-5p, hsa-miR-326, and hsa-miR-362-5p, the
expression levels are shown as the means of absolute amounts with standard deviations as compared with the PDR(–) group on a log10
scale. *P = 0.03.
expressed in PDR patients. Of these miRNAs, we
determined that the expression of hsa-miR-20a-5p,
hsa-miR-20a-23b-3p, hsa-miR-20a-142-3p, hsa-miR-
20a-185-5p, hsa-miR-20a-326, and hsa-miR-20a-362-
5p was higher in the vitreous of PDR patients. This
difference in miRNA expression also seems to be
independent of diabetes type. Furthermore, the expres-
sion of hsa-miR-23b-3p was lower in patients who had
received preoperative anti-VEGF treatment compared
with untreated PDR patients.
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Table 2. Validated and Predicted Gene Targets of miRNAs of Interest
miRNA Validated Targets Predicted Targets
hsa-miR-20a-5p BMP2, PDGFB, THBS1, VEGFA ANGPT1, ICAM1, IGFBP3, NRG1, UBB
hsa-miR-23b-3p — ADIPOQ, ANGPT2, BMP2, CTGF, HGF1, NRG1, PDGFB,
THBS1, VEGFA
hsa-miR-142-3p — ANGPT2, HGF, IGFBP3, NRG1, VEGFA
hsa-miR-185-5p VEGFA ADIPOQ, ANGPT2, BMP2, ICAM1, NOV, NRG1, PDGFB
hsa-miR-326 NOTCH1, NOTCH2 CTGF, GDF15, HGF, IGFBP2, IGFBP3,MMP2,MMP9,
NGFR, NOTCH3, NRG1, PDGFA, PDGFB, PDGFRB,
TIMP2, VEGFA
hsa-miR-362-5p — ADIPOQ, ANGPT1, ANGPT2,MMP2, NGFR, NRG1,
PDGFB, PDGFRA, PDGFRB, THBS1, TIMP2
Validated and predicted targets of miRNAs of interest were identified using miRTarBase29 and miRWalk,30 respectively. The
focus was on genes that are known to play a role in PDR and that are changed in the vitreous of PDR patients according to
Klaassen et al.31
Targets of Increased Vitreal miRNAs in PDR
Because we compared PDRpatients to non-diabetic
controls, the differences observed may be related to the
diabetic state, DR mechanisms in general, or specifi-
cally to PDR. However, all six miRNAs with elevated
expression in PDR patients can possibly target angio-
genic or profibrotic proteins that are increased in the
vitreous during PDR,31 including VEGF-A, angiopoi-
etin 2, platelet-derived growth factor B (PDGF-B),
and CTGF, which implies that these miRNAs may be
actively involved in regulating angiogenesis and wound
healing responses specific to PDR. The increase in
miRNA expression might be a compensatory mecha-
nism to decrease VEGF-A, angiopoietin 2, PDGF-B,
or other protein levels. On the other hand, protein levels
may be regulated by miRNAs in a different fashion.
One example is the interaction between miR-20a-5p
and VEGF, where miR-20a-5p targets VEGF but also
stimulates its expression.32 In contrast, VEGF itself
is able to increase the expression of miR-20a-5p.33
This indicates that the interplay between miRNAs and
their targets is complex, and further research on the
role of hsa-miR-20a-5p, miR-20a-23b-3p, miR-20a-
142-3p, miR-20a-185-5p, miR-20a-326, and miR-20a-
362-5p in PDR is necessary.
Association of Anti-VEGF Therapy with the
Vitreal miRNA Expression in PDR
Single preoperative anti-VEGF therapy 2 to 5 days
before surgery is a recognized treatment in PDR,34
particularly prior to vitrectomy in patients with active
neovascularization.35 Here, we observed that such anti-
VEGF therapy was associated with a lower expres-
sion of hsa-miR-23b-3p in PDR as compared with
untreated PDR patients. It should be noted in this
context that selection bias may be involved in the
composition of these two groups; nevertheless, as
VEGF increases the expression of hsa-miR-23b-3p,36
anti-VEGF therapy may result in a decrease of hsa-
miR-23b-3p expression. Anti-VEGF therapy, however,
may also influence the expression of miRNAs in ways
other than we have investigated. Additionally, different
anti-VEGF agents may also influence the expression of
different miRNAs.
Comparison with Other Studies Investigating
Vitreal miRNAs in PDR
Thus far, to the best of our knowledge, no other
studies have performed a large-scale miRNA inven-
tory in PDR patients as compared to controls with
groups of more than four patients. The team of Hirota
et al.19 was the first to publish differentially expressed
miRNAs in the vitreous of PDR patients as compared
with control patients with a macular hole, with four
patients in each group.No overlap inmiRNAswith our
studywas found, nor did we find a significant difference
in expression levels for miR-200b, a single miRNA that
was investigated by another group.20
The lack of overlap between our study and these two
studies may be explained by differences in screening
platforms, normalization methods, group sizes, patient
characteristics, and whether or not the results were
confirmed in subsequent experiments. However, this
lack of overlap also emphasizes the importance of
interpreting results carefully and highlights the need
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for standardized approaches, such as a standardized
method of normalization.
Normalization of Vitreal miRNAs
Onemajor challenge when investigating miRNAs in
body fluids is to reliably normalize their expression for
correct interpretation. The purpose of normalization
is to compensate for experimentally induced technical
variation, so sample variance after an effective normal-
ization strategy should be lower than when normal-
ization is not performed. We established that normal-
ization by global mean or UniSp6 as a spike-in did
not significantly improve sample variance compared
with no normalization, whereas other normalization
strategies or spike-ins significantly increased sample
variance. For this reason, we chose not to normal-
ize our data. In addition, we found snoU6, that is
commonly used to normalize miRNA expression,16,20
to be only sparsely expressed in our screening cohort,
which raises the question of whether or not snoU6 is
suitable for miRNA normalization in the vitreous.
Limitations
One limitation of the study is the use of panels
with predefined miRNAs for screening. Other methods
such as next-generation sequencing may result in the
identification of additional miRNAs. In addition, the
miRNA profile was examined only in the vitreous
of patients with end-stage PDR and compared to
non-diabetic controls. As indicated, the differences
observed may therefore be related to the diabetic state,
DR mechanisms in general, or specifically to PDR.
By investigating miRNA profiles in the vitreous of
patients with diabetes without DR, earlier stages of
DR and early PDR may shed further light on miRNA
expression over the course of DR, further illuminat-
ing the role of miRNAs in the progression of DR.
Finally, because preoperative anti-VEGF treatment
was indicated by the treating physician, selection bias
may have introduced other relevant differences between
the groups of PDR patients with or without anti-
VEGF patients.
Conclusions
We found the expression of hsa-miR-20a-5p, hsa-
miR-23b-3p, hsa-miR-142-3p, hsa-miR-185-5p, hsa-
miR-326, and hsa-miR-362-5p to be elevated in the
vitreous of PDR patients compared with controls.
These miRNAs are, therefore, interesting new candi-
dates to study in order to better understand the patho-
physiology of DR, particularly PDR. Furthermore,
anti-VEGF therapy was associated with lower levels of
hsa-miR-23b-3p in PDR patients, which may suggest
the involvement of a regulatory mechanism.
Future research should clarify how these miRNAs
influence the course of DR and PDR and if they can
serve either as biomarkers or as new therapeutic targets.
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